AAAAAA

   
Results: 1-25 | 26-50 | 51-53
Results: 1-25/53
DISIALOGANGLIOSIDE G(D2) LOSS FOLLOWING MONOCLONAL-ANTIBODY THERAPY IS RARE IN NEUROBLASTOMA
Authors: KRAMER K GERALD WL KUSHNER BH LARSON SM HAMEED M CHEUNG NKV
Citation: K. Kramer et al., DISIALOGANGLIOSIDE G(D2) LOSS FOLLOWING MONOCLONAL-ANTIBODY THERAPY IS RARE IN NEUROBLASTOMA, Clinical cancer research, 4(9), 1998, pp. 2135-2139
DETECTION OF MICROSCOPIC NEUROBLASTOMA IN MARROW BY HISTOLOGY, IMMUNOCYTOLOGY, AND REVERSE TRANSCRIPTION PCR OF MULTIPLE MOLECULAR MARKERS
Authors: CHEUNG IY BARBER D CHEUNG NKV
Citation: Iy. Cheung et al., DETECTION OF MICROSCOPIC NEUROBLASTOMA IN MARROW BY HISTOLOGY, IMMUNOCYTOLOGY, AND REVERSE TRANSCRIPTION PCR OF MULTIPLE MOLECULAR MARKERS, Clinical cancer research, 4(11), 1998, pp. 2801-2805
3F8 MONOCLONAL-ANTIBODY TREATMENT OF PATIENTS WITH STAGE-4 NEUROBLASTOMA - A PHASE-II STUDY
Authors: CHEUNG NKV KUSHNER BH YEH SDJ LARSON SM
Citation: Nkv. Cheung et al., 3F8 MONOCLONAL-ANTIBODY TREATMENT OF PATIENTS WITH STAGE-4 NEUROBLASTOMA - A PHASE-II STUDY, International journal of oncology, 12(6), 1998, pp. 1299-1306
HIGH-RISK OF LEUKEMIA AFTER SHORT-TERM DOSE-INTENSIVE CHEMOTHERAPY INYOUNG-PATIENTS WITH SOLID TUMORS
Authors: KUSHNER BH HELLER G CHEUNG NKV WOLLNER N KRAMER K BAJORIN D POLYAK T MEYERS PA
Citation: Bh. Kushner et al., HIGH-RISK OF LEUKEMIA AFTER SHORT-TERM DOSE-INTENSIVE CHEMOTHERAPY INYOUNG-PATIENTS WITH SOLID TUMORS, Journal of clinical oncology, 16(9), 1998, pp. 3016-3020
ANTI-GD(2) ANTIBODY TREATMENT OF MINIMAL RESIDUAL STAGE-4 NEUROBLASTOMA DIAGNOSED AT MORE THAN 1 YEAR OF AGE
Authors: CHEUNG NKV KUSHNER BH CHEUNG IY KRAMER K CANETE A GERALD W BONILLA MA FINN R YEH SJ LARSON SM
Citation: Nkv. Cheung et al., ANTI-GD(2) ANTIBODY TREATMENT OF MINIMAL RESIDUAL STAGE-4 NEUROBLASTOMA DIAGNOSED AT MORE THAN 1 YEAR OF AGE, Journal of clinical oncology, 16(9), 1998, pp. 3053-3060
ASSOCIATION OF CYP3A4 GENOTYPE WITH TREATMENT-RELATED LEUKEMIA
Authors: FELIX CA WALKER AH LANGE BJ WILLIAMS TM WINICK NJ CHEUNG NKV LOVETT BD NOWELL PC BLAIR IA REBBECK TR
Citation: Ca. Felix et al., ASSOCIATION OF CYP3A4 GENOTYPE WITH TREATMENT-RELATED LEUKEMIA, Proceedings of the National Academy of Sciences of the United Statesof America, 95(22), 1998, pp. 13176-13181
PHARMACOKINETICS OF IGG AND IGM ANTIGANGLIOSIDE ANTIBODIES IN RATS AND MONKEYS AFTER INTRATHECAL ADMINISTRATION
Authors: BERGMAN I BURCKART GJ POHL CR VENKATARAMANAN R BARMADA MA GRIFFIN JA CHEUNG NKV
Citation: I. Bergman et al., PHARMACOKINETICS OF IGG AND IGM ANTIGANGLIOSIDE ANTIBODIES IN RATS AND MONKEYS AFTER INTRATHECAL ADMINISTRATION, The Journal of pharmacology and experimental therapeutics, 284(1), 1998, pp. 111-115
ANTIGEN-DEPENDENT CD28 SIGNALING SELECTIVELY ENHANCES SURVIVAL AND PROLIFERATION IN GENETICALLY-MODIFIED ACTIVATED HUMAN PRIMARY T-LYMPHOCYTES
Authors: KRAUSE A GUO HF LATOUCHE JB TAN CW CHEUNG NKV SADELAIN M
Citation: A. Krause et al., ANTIGEN-DEPENDENT CD28 SIGNALING SELECTIVELY ENHANCES SURVIVAL AND PROLIFERATION IN GENETICALLY-MODIFIED ACTIVATED HUMAN PRIMARY T-LYMPHOCYTES, The Journal of experimental medicine, 188(4), 1998, pp. 619-626
ANTIBODIES AGAINST GD2 GANGLIOSIDE CAN ERADICATE SYNGENEIC CANCER MICROMETASTASES
Authors: ZHANG H ZHANG SL CHEUNG NKV RAGUPATHI G LIVINGSTON PO
Citation: H. Zhang et al., ANTIBODIES AGAINST GD2 GANGLIOSIDE CAN ERADICATE SYNGENEIC CANCER MICROMETASTASES, Cancer research, 58(13), 1998, pp. 2844-2849
MOLECULAR-DETECTION OF GAUGE EXPRESSION IN PERIPHERAL-BLOOD AND BONE-MARROW - UTILITY AS A TUMOR-MARKER FOR NEUROBLASTOMA
Authors: CHEUNG IY CHEUNG NKV
Citation: Iy. Cheung et Nkv. Cheung, MOLECULAR-DETECTION OF GAUGE EXPRESSION IN PERIPHERAL-BLOOD AND BONE-MARROW - UTILITY AS A TUMOR-MARKER FOR NEUROBLASTOMA, Clinical cancer research, 3(5), 1997, pp. 821-826
MONOCLONAL-ANTIBODY TO HUMAN TRK-A - DIAGNOSTIC AND THERAPEUTIC POTENTIAL IN NEUROBLASTOMA
Authors: KRAMER K GERALD W LESAUTEUR L SARAGOVI HU CHEUNG NKV
Citation: K. Kramer et al., MONOCLONAL-ANTIBODY TO HUMAN TRK-A - DIAGNOSTIC AND THERAPEUTIC POTENTIAL IN NEUROBLASTOMA, European journal of cancer, 33(12), 1997, pp. 2090-2091
CORRELATION OF MYCN AMPLIFICATION, TRK-A AND CD44 EXPRESSION WITH CLINICAL STAGE IN 250 PATIENTS WITH NEUROBLASTOMA
Authors: KRAMER K CHEUNG NKV GERALD WL LAQUAGLIA M KUSHNER BH LECLERC JM LESAUTER L SARAGOVI HU
Citation: K. Kramer et al., CORRELATION OF MYCN AMPLIFICATION, TRK-A AND CD44 EXPRESSION WITH CLINICAL STAGE IN 250 PATIENTS WITH NEUROBLASTOMA, European journal of cancer, 33(12), 1997, pp. 2098-2100
SURVIVAL FROM NON-STAGE-4 NEUROBLASTOMA WITHOUT CYTOTOXIC THERAPY - AN ANALYSIS OF CLINICAL AND BIOLOGICAL MARKERS
Authors: CHEUNG NKV KUSHNER BH LAQUAGLIA MP KRAMER K AMBROS P AMBROS I LADANYI M EDDY J BONILLA MA GERALD W
Citation: Nkv. Cheung et al., SURVIVAL FROM NON-STAGE-4 NEUROBLASTOMA WITHOUT CYTOTOXIC THERAPY - AN ANALYSIS OF CLINICAL AND BIOLOGICAL MARKERS, European journal of cancer, 33(12), 1997, pp. 2117-2120
DETECTION OF METASTATIC NEUROBLASTOMA IN BONE-MARROW - WHEN IS ROUTINE MARROW HISTOLOGY INSENSITIVE
Authors: CHEUNG NKV HELLER G KUSHNER BH LIU CY CHEUNG IY
Citation: Nkv. Cheung et al., DETECTION OF METASTATIC NEUROBLASTOMA IN BONE-MARROW - WHEN IS ROUTINE MARROW HISTOLOGY INSENSITIVE, Journal of clinical oncology, 15(8), 1997, pp. 2807-2817
HYPERFRACTIONATED RADIOTHERAPY (2100 CGY) FOR STAGE-4 NEUROBLASTOMA AS PART OF INTENSIVE MULTIMODALITY THERAPY
Authors: GOLLAMUDI SV KUSHNER BH MERCHANT TE LAQUAGLIA M LINDSLEY K ROSENFIELD N ABRAMSON S KRAMER K CHEUNG NKV
Citation: Sv. Gollamudi et al., HYPERFRACTIONATED RADIOTHERAPY (2100 CGY) FOR STAGE-4 NEUROBLASTOMA AS PART OF INTENSIVE MULTIMODALITY THERAPY, International journal of radiation oncology, biology, physics, 39(2), 1997, pp. 336-336
ADDITIVE CYTOTOXICITY OF DIFFERENT MONOCLONAL-ANTIBODY COBRA VENOM FACTOR CONJUGATES FOR HUMAN NEUROBLASTOMA-CELLS
Authors: JUHL H PETRELLA EC CHEUNG NKV BREDEHORST R VOGEL CW
Citation: H. Juhl et al., ADDITIVE CYTOTOXICITY OF DIFFERENT MONOCLONAL-ANTIBODY COBRA VENOM FACTOR CONJUGATES FOR HUMAN NEUROBLASTOMA-CELLS, Immunobiology, 197(5), 1997, pp. 444-459
PHARMACOKINETICS AND ACUTE TOXICOLOGY OF INTRAVENTRICULAR I-131 MONOCLONAL-ANTIBODY TARGETING DISIALOGANGLIOSIDE IN NONHUMAN-PRIMATES
Authors: KRAMER K CHEUNG NKV HUMM J DIRESTA G ARBIT E LARSON S FINN R ROSENBLUM M NGUYEN H GONZALEZ G LIU CJ YANG YF MENDELSOHN ME GILLIO AP
Citation: K. Kramer et al., PHARMACOKINETICS AND ACUTE TOXICOLOGY OF INTRAVENTRICULAR I-131 MONOCLONAL-ANTIBODY TARGETING DISIALOGANGLIOSIDE IN NONHUMAN-PRIMATES, Journal of neuro-oncology, 35(2), 1997, pp. 101-111
A RAT MODEL OF LEPTOMENINGEAL HUMAN NEOPLASTIC XENOGRAFTS
Authors: BERGMAN I AHDABBARMADA M KEMP SS GRIFFIN JA CHEUNG NKV
Citation: I. Bergman et al., A RAT MODEL OF LEPTOMENINGEAL HUMAN NEOPLASTIC XENOGRAFTS, Journal of neuro-oncology, 34(3), 1997, pp. 221-231
SMALL-MOLECULE NERVE GROWTH-FACTOR ANALOGS IMAGE RECEPTORS IN-VIVO
Authors: LESAUTEUR L CHEUNG NKV LISBONA R SARAGOVI HU
Citation: L. Lesauteur et al., SMALL-MOLECULE NERVE GROWTH-FACTOR ANALOGS IMAGE RECEPTORS IN-VIVO, Nature biotechnology, 14(9), 1996, pp. 1120-1122
PROGNOSTIC VALUE OF TRKA PROTEIN-DETECTION BY MONOCLONAL-ANTIBODY 5C3IN NEUROBLASTOMA
Authors: KRAMER K GERALD W LESAUTEUR L SARAGOVI HU CHEUNG NKV
Citation: K. Kramer et al., PROGNOSTIC VALUE OF TRKA PROTEIN-DETECTION BY MONOCLONAL-ANTIBODY 5C3IN NEUROBLASTOMA, Clinical cancer research, 2(8), 1996, pp. 1361-1367
KINETICS OF PRIMARY TUMOR-REGRESSION WITH CHEMOTHERAPY - IMPLICATIONSFOR THE TIMING OF SURGERY
Authors: MEDARY I ARONSON D CHEUNG NKV GHAVIMI F GERALD W LAQUAGLIA MP
Citation: I. Medary et al., KINETICS OF PRIMARY TUMOR-REGRESSION WITH CHEMOTHERAPY - IMPLICATIONSFOR THE TIMING OF SURGERY, Annals of surgical oncology, 3(6), 1996, pp. 521-525
COMPARISON OF THE TARGETING CHARACTERISTICS OF VARIOUS RADIOIMMUNOCONJUGATES FOR RADIOIMMUNOTHERAPY OF NEUROBLASTOMA - DOSIMETRY CALCULATIONS INCORPORATING CROSS-ORGAN BETA DOSES
Authors: UGUR O KOSTAKOGLU L HUI ET FISHER DR GARMESTANI K GANSOW OA CHEUNG NKV LARSON SM
Citation: O. Ugur et al., COMPARISON OF THE TARGETING CHARACTERISTICS OF VARIOUS RADIOIMMUNOCONJUGATES FOR RADIOIMMUNOTHERAPY OF NEUROBLASTOMA - DOSIMETRY CALCULATIONS INCORPORATING CROSS-ORGAN BETA DOSES, Nuclear medicine and biology, 23(1), 1996, pp. 1-8
INTERNATIONAL NEUROBLASTOMA STAGING SYSTEM STAGE-1 NEUROBLASTOMA - A PROSPECTIVE-STUDY AND LITERATURE-REVIEW
Authors: KUSHNER BH CHEUNG NKV LAQUAGLIA MP AMBROS PF AMBROS IM BONILLA MA LADANYI M GERALD WL
Citation: Bh. Kushner et al., INTERNATIONAL NEUROBLASTOMA STAGING SYSTEM STAGE-1 NEUROBLASTOMA - A PROSPECTIVE-STUDY AND LITERATURE-REVIEW, Journal of clinical oncology, 14(7), 1996, pp. 2174-2180
DESMOPLASTIC SMALL ROUND-CELL TUMOR - PROLONGED PROGRESSION-FREE SURVIVAL WITH AGGRESSIVE MULTIMODALITY THERAPY
Authors: KUSHNER BH LAQUAGLIA MP WOLLNER N MEYERS PA LINDSLEY KL GHAVIMI F MERCHANT TE BOULAD F CHEUNG NKV BONILLA MA CROUCH G KELLEHER JF STEINHERZ PG GERALD WL
Citation: Bh. Kushner et al., DESMOPLASTIC SMALL ROUND-CELL TUMOR - PROLONGED PROGRESSION-FREE SURVIVAL WITH AGGRESSIVE MULTIMODALITY THERAPY, Journal of clinical oncology, 14(5), 1996, pp. 1526-1531
SURVIVAL FROM LOCALLY INVASIVE OR WIDESPREAD NEUROBLASTOMA WITHOUT CYTOTOXIC THERAPY
Authors: KUSHNER BH CHEUNG NKV LAQUAGLIA MP AMBROS PF AMBROS IM BONILLA MA GERALD WL LADANYI M GILBERT F ROSENFIELD NS YEH SDJ
Citation: Bh. Kushner et al., SURVIVAL FROM LOCALLY INVASIVE OR WIDESPREAD NEUROBLASTOMA WITHOUT CYTOTOXIC THERAPY, Journal of clinical oncology, 14(2), 1996, pp. 373-381
Risultati: 1-25 | 26-50 | 51-53